Tenofovir treatment duration predicts proteinuria in a multi-ethnic united states cohort of children and adolescents with perinatal HIV-1 infection

Murli Purswani, Kunjal Patel, Jeffrey B. Kopp, George R. Seage, Miriam C. Chernoff, Rohan Hazra, George K. Siberry, Lynne M. Mofenson, Gwendolyn B. Scott, Russell B. Van Dyke

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: Tenofovir is associated with renal proximal tubule injury. Such toxicity has not been extensively studied in HIV-1-infected children, in whom tenofovir is increasingly used. METHODS: History, urine and blood were collected at regular intervals from 448 children and adolescents with perinatal HIV-1 infection followed in the Pediatric HIV/AIDS Cohort study. Relationships between tenofovir use and proteinuria and chronic kidney disease (CKD) outcomes were examined using multivariable logistic regression models. Proteinuria was defined as at least one urine protein/creatinine ratio (uPCR) ≥0.2, and CKD as ≥2 sequential uPCR ≥0.2 or estimated glomerular filtration rates (eGFR) 3 years of exposure having the highest risk compared with no exposure (OR: 2.53, 95% CI: 1.23- 5.22, overall p=0.01). Overall, duration of tenofovir use did not significantly predict the presence of CKD. CONCLUSIONS: Rates of proteinuria and CKD were lower than those seen in the pre-HAART era. However, prolonged exposure to tenofovir increases risk of renal injury.

Original languageEnglish (US)
JournalPediatric Infectious Disease Journal
DOIs
StateAccepted/In press - Dec 17 2012
Externally publishedYes

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pediatrics, Perinatology, and Child Health

Fingerprint

Dive into the research topics of 'Tenofovir treatment duration predicts proteinuria in a multi-ethnic united states cohort of children and adolescents with perinatal HIV-1 infection'. Together they form a unique fingerprint.

Cite this